Gene Therapy in Recurrent Glioma Shows Promise in Early TrialCancer NetworkMore than 25% of patients with recurrent, high-grade glioma treated with a gene therapy combination were alive more than 3 years after treatment, according to data from a subset… Continue reading
Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In PatientsGlobeNewswire (press release)“Not all patients respond to immunotherapies,” said Dr. Heinrich Roder. “The pre-treatment circulating proteom… Continue reading
Medical Xpress |
A ‘CRISPR‘ view of Sturge-Weber syndrome is coming into focus
Medical Xpress Three-dimensional modeling and CRISPR-Cas9 gene editing technology are giving scientists a new view into Sturge-Weber syndrome, a rare congenital disorder that causes small blood vessels, called capillaries, to be malformed. These capillary … |
Medical Xpress |
A ‘CRISPR‘ view of Sturge-Weber syndrome is coming into focus
Medical Xpress Three-dimensional modeling and CRISPR-Cas9 gene editing technology are giving scientists a new view into Sturge-Weber syndrome, a rare congenital disorder that causes small blood vessels, called capillaries, to be malformed. These capillary … |
Philadelphia Business Journal |
Spark, Pfizer amend agreement for experimental hemophilia gene therapy
Philadelphia Business Journal Under the amended agreement, Spark Therapeutics, a Philadelphia gene therapy company spun out of Children’s Hospital of Philadelphia, will enroll up to five additional participants in the current phase-I/II clinical trial testing the treatment known as … Spark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia BStreetInsider.com |
Philadelphia Business Journal |
Spark, Pfizer amend agreement for experimental hemophilia gene therapy
Philadelphia Business Journal Under the amended agreement, Spark Therapeutics, a Philadelphia gene therapy company spun out of Children’s Hospital of Philadelphia, will enroll up to five additional participants in the current phase-I/II clinical trial testing the treatment known as … Spark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia BStreetInsider.com |
Technology Networks |
Autonomously Growing Synthetic DNA Strands
Technology Networks Synthetic biologists and nanobiologists are re-purposing DNA, the hereditary material present in nearly all the body’s cells, as a smart and stable self-assembling material to build nanofactories, drug-delivering nanostructures and molecular devices … |